Severe bacterial pneumonia remains a major cause of death in critically ill patients, largely due to impaired early immune responses. New research reveals that butyric acid, a metabolite produced by ...
Sepsis and severe pneumonia are frequently accompanied by disruption of the gut microbiota, leading to immune dysfunction and ...
The immune system's killer cells deliver a tightly controlled, 3-phase knockout punch that kills intracellular parasites through a novel pathway that an international team led by researchers from the ...
Liver fibrosis, a progressive scarring of the liver tissue, represents a major global health burden with limited treatment options. It is primarily driven by the activation of hepatic stellate cells ...
Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 clinical study evaluating a novel chemotherapy-free and ...
A 'game changing' new technique which wipes out rogue cells responsible for autoimmune conditions may offer the hope of a one-off treatment for many debilitating diseases. Around four million people ...
Chronic diabetic ulcers represent one of the most challenging complications in modern healthcare, affecting over 131 million people worldwide and generating approximately $755 billion in annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results